Personalized immunosuppression after kidney transplantation
With advances in immunosuppressive therapy, there have been significant improvements in
acute rejection rates and short‐term allograft survival in kidney transplant recipients …
acute rejection rates and short‐term allograft survival in kidney transplant recipients …
Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations
JT Tang, LM Andrews, T van Gelder… - Expert opinion on …, 2016 - Taylor & Francis
ABSTRACT Introduction: Tacrolimus (Tac) is effective in preventing acute rejection but has
considerable toxicity and inter-individual variability in pharmacokinetics and …
considerable toxicity and inter-individual variability in pharmacokinetics and …
Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome?
T van Gelder, DA Hesselink - Clinical Pharmacology & …, 2010 - Wiley Online Library
Tacrolimus, widely used to prevent acute rejection following solid‐organ transplantation, has
become the cornerstone of immunosuppressive therapy after kidney transplantation. More …
become the cornerstone of immunosuppressive therapy after kidney transplantation. More …
[HTML][HTML] A randomized controlled trial comparing the efficacy of Cyp3a5 genotype‐based with body‐weight‐based tacrolimus dosing after living donor kidney …
N Shuker, R Bouamar, RHN van Schaik… - American Journal of …, 2016 - Elsevier
Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose
to achieve therapeutic exposure compared with nonexpressers. This randomized‐controlled …
to achieve therapeutic exposure compared with nonexpressers. This randomized‐controlled …
Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation
S Vannaprasaht, S Reungjui, D Supanya… - Clinical …, 2013 - Elsevier
Abstract Background Cytochrome P450 (CYP) 3A4 and 3A5 are major isoforms involved in
the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is …
the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is …
In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients
H De Jonge, H De Loor, K Verbeke… - Clinical …, 2012 - Wiley Online Library
Tacrolimus is metabolized by CYP3A4 and CYP3A5 and is characterized by a narrow
therapeutic index and highly variable pharmacokinetics. This cross‐sectional study in 59 …
therapeutic index and highly variable pharmacokinetics. This cross‐sectional study in 59 …
Which genetic determinants should be considered for tacrolimus dose optimization in kidney transplantation? A combined analysis of genes affecting the CYP3A locus
H Bruckmueller, AN Werk, L Renders… - Therapeutic drug …, 2015 - journals.lww.com
Background: Tacrolimus is established as immunosuppressant after kidney transplantation.
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …
A decade of progress in kidney transplantation
F Vincenti - Transplantation, 2004 - journals.lww.com
Kidney transplantation has become the treatment of choice for patients with end-stage renal
disease because of better surgical techniques and the availability of more powerful …
disease because of better surgical techniques and the availability of more powerful …
Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype‐guided doses in renal …
S Anutrakulchai, C Pongskul… - British Journal of …, 2019 - Wiley Online Library
Aims Although cytochromeP450 (CYP) 3A5 gene polymorphism affects personalized
tacrolimus doses, there is no consensus as to whether CYP3A5 genotypes should be …
tacrolimus doses, there is no consensus as to whether CYP3A5 genotypes should be …
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients
DA Hesselink, RHN van Schaik… - Pharmacogenetics …, 2008 - journals.lww.com
Objective Patients expressing the tacrolimus-metabolizing enzyme, cytochrome P450 (CYP)
3A5, require more tacrolimus to reach target concentrations. We studied the influence of the …
3A5, require more tacrolimus to reach target concentrations. We studied the influence of the …